Superworth

Amphastar Pharmaceuticals EV/EBIT AMPH

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2016.

Today, Oct 23, 2026
12.2×
10-year median
18.7×
Against its 10-year history
31st
percentile: 0 is its lowest day, 100 its highest
10-year range
6.9× to 499×
Peer median
6.3×

Amphastar Pharmaceuticals' EV/EBIT is 12.2× as of Oct 23, 2026.

That is below its ten-year median of 18.7×, lower than on 69% of days in the last ten years.

Over that time it ranged from 6.9× in Jul 2025 to 499× in Sep 2019.

The median for 10 large drugmakers of a similar size is 6.3×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far12.2×8.3×12.7×
202510.5×6.9×10.7×
202410.1×10.0×18.3×
202318.1×13.7×24.4×
202213.3×13.0×33.1×
202122.2×18.9×119×
2020121×81.7×495×
2019478×442×499×
2018n/m a value too high to mean anything
2017174×18.5×174×
201623.5×23.5×156×

Against its peers

Companies in Drug Manufacturers - General nearest Amphastar Pharmaceuticals' size, closest first, today.

CompanyEV/EBIT
AMPHAmphastar Pharmaceuticals12.2×
OMEROmerosn/m
ABUSArbutus Biopharma4.9×
PCRXPacira BioSciences7.6×
ANABAnaptysbion/m
COLLCollegium Pharmaceutical9.4×
PAHCPhibro Animal Health11.7×
ANIPANI Pharmaceuticals10.5×
CRMDCorMedix2.3×
ZVRAZevra Therapeutics2.9×
IRWDIronwood Pharmaceuticals3.5×
Peer median6.3×

Where Amphastar Pharmaceuticals ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Amphastar Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.